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Abstract.  The nuclear  lamina proteins,  prelamin  A, 
lamin  B, and a  70-kD  lamina-associated  protein,  are 
posttranslationally  modified by a  metabolite derived 
from mevalonate.  This  modification can be inhibited 
by treatment  with (3-R,S)-3-fluoromevalonate,  demon- 
strating  that  it is isoprenoid  in nature.  We have exam- 
ined the association between isoprenoid  metabolism 
and processing  of the lamin  A  precursor  in human  and 
hamster  cells.  Inhibition  of 3-hydroxy-3-methylglutaryl 
coenzyme A  reductase  by mevinolin  (lovastatin) 
specifically depletes endogenous  isoprenoid  pools and 
inhibits the conversion  of prelamin  A  to lamin  A. 
Prelamin  A  processing  is also blocked by mevalonate 
starvation  of Mev-1, a  CHO cell line auxotrophic  for 
mevalonate.  Moreover,  inhibition  of prelamin  A  pro- 
cessing by mevinolin  treatment  is rapidly  reversed by 
the addition  of exogenous mevalonate.  Processing  of 
prelamin  A  is,  therefore,  dependent on isoprenoid  me- 
tabolism.  Analysis of the conversion of prelamin  A  to 
lamin  A  by two independent  methods,  immunoprecipi- 
tation  and two-dimensional  nonequilibrium  pH gel 
electrophoresis,  demonstrates  that a  precursor-product 
relationship  exists between prelamin  A  and lamin  A. 
Analysis of R,S-[5-3H(N)]mevalonate-labeled  cells 
shows that the rate of turnover of the isoprenoid group 
from prelamin  A  is comparable  to the rate of conver- 
sion of prelamin  A  to lamin  A.  These  results~ suggest 
that during  the proteolytic  maturation  of prelamin  A, 
the isoprenylated  moiety is lost.  A  significant  differ- 
ence between prelamin  A  processing,  and that of p21 ra~ 
and the B-type lamins  that  undergo  isoprenylation- 
dependent proteolytic maturation,  is that the mature 
form of lamin  A  is no longer  isoprenylated. 
T 
HREE major polypeptides termed lamins A, B, and C 
(14,  17) comprise the nuclear lamina (1, 11, 16, 27, 28) 
of most mammalian  somatic cells. Individual  lamins 
are  substrates  for  posttranslational  modifications  that  in- 
clude cell cycle-dependent phosphorylation  (7,  15, 37,  42, 
52),  methyl-esterification  (9),  and  covalent  modification 
with a mevalonate-derived product (4, 6, 34, 47, 49, 50, 58). 
The transient depolymerization of lamins, an event that is as- 
sociated with the hyperphosphorylation of lamins (7, 14,  15, 
37,  42)  during  mitosis,  has  been  suggested to play a  key 
regulatory role in the concomitant dissociation and reforma- 
tion of the nuclear envelope. Membrane association appears 
to  be  an  important  function  of  the  mevalonate-derived 
modifications to lamins in light of the apparent nuclear mem- 
brane  localization  of mammalian  lamin  B  (7,  15,  18,  31), 
chicken lamin B2 (55), and the lamin A precursor polypep- 
tide  (22),  all  of which  are  modified by isoprenoids.  The 
isoprenoid  substituent  of lamin  B(lla),  p21 ra~ (8,  46),  and 
yeast polypeptide pheromones (3, 23, 25, 39, 45) has been 
identified as farnesyl. 
Gerace et al. (17) have shown that in CHO cells, prelamin 
A becomes NP-40 insoluble within 5 min of synthesis, and 
that it is in this lamina-associated environment that process- 
ing to mature lamin A occurs. We have previously reported 
(4) that this 74-kD precursor form of lamin A is posttransla- 
tionally modified by a metabolic product derived from R-[2- 
~4C]mevalonate.  Site-specific  point  mutation  and  deletion 
analyses have established that the carboxy-terminal -cysteine- 
aliphatic-aliphatic-methionine  (-C-A-A-M) ~ motif, acting in 
concert with other signal sequences, is required for efficient 
targeting of human prelamin A (22) and Xenopus lamins L~ 
and A (29) to the nuclear membrane. In mammalian (4, 17, 
30, 42, 56) and avian (33, 55) cells, prelamin A to !amin A 
maturation is associated with a 2-kD decrease in molecular 
mass. We have demonstrated (4) that, after this maturation 
event, lamin A no longer contains the R-[2-~4C] mevalonate- 
derived moiety. 
In this  report,  we examine the processing of the 74-kD 
prelamin  A  precursor  polypeptide  in  human  (HeLa)  and 
hamster  (CHO-K1) cells. The requirement  for mevalonate, 
and hence, isoprenoids, for the conversion of prelamin A to 
lamin A is demonstrated both in cultured cells treated with 
mevinolin  as well as by mevalonate starvation of mev-1,  a 
CHO-KI  mevalonate  auxotroph.  The  results  presented  in 
this report are consistent with the existence of an isoprenyl- 
ation-dependent pathway for the formation of mature lamin 
A, and support our earlier proposal (4) that isoprenylation 
1. Abbreviations used in this paper: -C-A-A-M, cysteine-aliphatic-aliphatic- 
methionine;  -C-A-A-X, cysteine-aliphatic-aliphatic-other; 2D-NEPHGE, 
two-dimensional nonequilibrium pH gradient electrophoresis. 
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isoprenylated proteins. 
Materials and Methods 
Materials 
R-[2-14C]mevalonic acid  lactone  (56.7  Ci/mmol,  2.10  GBq/mmol)  was 
purchased from Amersham Corp. (Arlington Heights, IL); R,S-15-3H(N)] - 
mevalonolactone (24 Ci/mmol, 888.0 GBq/mmol) from New England Nu- 
clear (Boston, MA); and [35S]methionine (tran35S-label,  1,005  Ci/mmol) 
from ICN Radiochemicals (h'vine, CA). Mevinolin (Iovastatin) was a gift 
from A. W. Alberts of Merck, Sharp, and Dohme (Rahway, NJ). (3-R,S)-3- 
fluoromevalonate was a gift of Zoecon Corporation (Palo Alto, CA). Triton 
X-100 and SDS (surfact-amps) were from Pierce Chemical Company (Rock- 
ford, IL). Nitrocellulose membranes (trans-blot) and all reagents used for 
SDS-PAGE were from Bio-Rad Laboratories (Richmond, CA). Silver-stain 
"DPC" kit was from Integrated Separation Systems (Hyde Park, MA). Mo- 
lecular mass marker standards were from Pharmacia Fine Chemicals (Upp- 
sala,  Sweden).  Ampholytes (Is'o-Dalt Grade) were from Serva Fine Bio- 
chemicals Inc. (Garden City Park, NJ). DNase I (Code:DP) and RNase A 
(Code:RASE) were from Organon Teknika-Cappel (Malvern, PA). Antila- 
min (A +  C) human autoimmune serum (35) was a gift of Dr. E  McKeon 
(Harvard Medical School); normal human serum was from Rockland, Inc. 
(Gilbertsville, PA), and protein A-Sepharose CL-4B was from Sigma Chem- 
ical Co.  (St.  Louis,  MO).  Goat anti-human IgG (H  +  L  chain)-alkaline 
phosphatase antibody conjugate and Immun-BIot Assay Kits were from Bio- 
Rad Laboratories.  A CHO-KI  derivative, met-18b-2, was a gift from Dr. 
J. Faust (Tufts University, Boston, MA). All cell culture reagents were from 
Gibeo Laboratories (Grand Island, NY). Fungizone (Amphotericin B) was 
obtained from E. R. Squibb (Princeton, N J). All other chemicals were pur- 
chased from Sigma Chemical Co. 
Cell Culture and Radioisotopic  Labeling 
The cell lines used were CHO-K1  (26);  mev-l, a  CHO-Ki  3-hydroxy-3- 
methylglutaryl CoA synthase mutant (48, 5 l); met-18b-2, a CHO cell line 
that displays elevated mevalonate uptake and metabolism 02), and HeLa, 
a human adenocarcinoma cell line (24).  Cells were grown in Ham's F12 
medium (20), supplemented with FCS (5 % lvol/vol] for CHO cell lines and 
10% [vol/vol] for HeLa),  100 U/ml penicillin, 100 #g/ml streptomycin, and 
1 #g/ml Fungizone (medium I). Mev-1 cells were grown in medium I sup- 
plemented with 60 #g/ml  mevalonate (medium II).  Met-18b-2 cells were 
grown in medium I supplemented as described (12) with 8 #g/ml mevinolin 
and 37 #g/ml mevalonate (medium III). 
For  labeling  with  R,S-[5-3H(N)]mevalonate  or  R-[214C]mevalonate, 
cells were plated in the appropriate medium at one-half maximum density, 
and allowed  to attach overnight.  Before addition of mevalonate labeling 
medium, the cells were washed with PBS (130 mM NaCI,  2  mM KCI, 8 
mM  Na2HPO4,  2  mM  KH2PO4,  pH 7.2).  Mevalonate labeling medium 
consisted of F12, penicillin, streptomycin, Fungizone, and 5% (vol/vol) dia- 
lyzed (against PBS) FCS (medium IV), and was supplemented with radiola- 
beled mevalonate (either 2-10 #Ci/ml of R-[2-14C]mevalonic acid lactone 
or  10 t~Ci/ml R,S-[5-3H(N)]mevalonolactone)  with the appropriate con- 
centrations of mevinolin (details are given in the figure legends).  Mev-l 
cells are auxotrophic for mevalonate, and do not require mevinolin treat- 
ment to block endogenous mevalonate synthesis. [35S]Methionine labeling 
medium (medium V) consisted of F12 containing one-half the normal me- 
thionine concentration, penicillin, streptomycin, Fungizone, 5% (vol/vol) 
dialyzed FCS,  and  100 #Ci/ml [3SS]methionine. 
Electrophoresis  and Western Blotting 
SDS-PAGE, two-dimensional nonequilibrium pH gel electrophoresis (2D- 
NEPHGE), and fluorography were performed as previously described (4). 
E!ectrophoretic transfer of proteins to nitrocellulose membranes was per- 
formed at 4°C for 12-14 h at 30 V (100 mA) using a Hoefer TE Series Trans- 
phor Electrophoresis Unit (Hoefer Scientific Products, San Francisco, CA) 
in the Tris-glycine-methanol buffer system of Towbin (54) containing 0.1% 
(wt/vol) SDS. 
lmmunoblot Analysis of Proteins Immobilized 
on Nitrocellulose 
After electrophoretic transfer of proteins from the two-dimensional nonequi- 
librium pH gradient electrophoresis (2D-NEPHGE) gel, the nitrocellulose 
membrane was rinsed in TBS (20 mM Tris-HCi, pH 7.5,  500 mM NaCI) 
and blocked overnight at 4"C in TBS blocking buffer (TBS, 0.5% [vol/vol] 
Tween-20 and 5 % [wt/voll BSA [RIA gradeD. The nitnx~ilulose membrane 
was then rinsed in TBS and placed in 5 ml of TBS blocking buffer containing 
a  1:1,000 dilution of LSI anti-lamin (A +  C) antiserum (35). After incuba- 
tion for 6-12 h at 4°C with the primary antibody, the nitrocellulose mem- 
brane was washed twice in TBS with 0,05% Tween-20 for 10 rain at 4"C. 
The nitrocellulose membrane was then reacted with goat anti-human IgG- 
alkaline pbosphatase conjugate at a  l:l,000 dilution in TBS, 5% (wffvol) 
BSA for 1-2 b at 25°C. The nitrocellulose membrane was then rinsed three 
times for 5 rain in TBS. Color development of the alkaline phosphatase- 
conjugated second antibody was performed according to the manufacturer's 
directions. 
Filter Binding  Assay for p~S]methionine and 
R-[2-UC]mevalonate-labeled  Proteins 
A  small fraction of the R-[2-14Clmevalonate is incorporated into isopen- 
tenyl tRNA (47, 50), which must be hydrolyzed (100 #g/ml RNase A, 37°C, 
30 min) before precipitation of proteins with TCA.  Carder  protein and 
lipids were added in the form of FCS (20 #l/assay). The samples were then 
adjusted to  10%  (wt/vol) 'IV_A, and incubated on ice for at least 60 rain. 
Samples were transferred to GF/A glass microfiber filters (Whatman Inc., 
Clifton, NJ) and washed sequentially with three 5-mi volumes each of ace- 
tone, followed by chloroform:methanol (2/1), and 95% ethanol. The filters 
were dried and radioactivity determined. 
Results 
Inhibition of  Mevalonate Biosynthesis Prevents the 
Conversion of Prelamin A to Lamin A 
We have demonstrated (4) that growth of mammalian cells 
in the presence of mevinolin and R-[2-~4C]mevalonate re- 
sults in the labeling of three proteins present in nuclear lam- 
ina intermediate filament preparations.  These R-[2-14C]mev  - 
alonate-labeled proteins are present in a number of different 
cell lines (Beck, L. A., C. H. Campbell, J. Logel, and M. 
Sinensky, submitted for publication) including HeLa and 
CHO. Proteins visualized by silver-staining of a 2D-NEPHGE 
gel of nuclear lamina intermediate filament preparations  from 
R-[2-~4C]mevalonate labeled CHO-KI (Fig.  I A) are lamin 
A  (72 kD), lamin B (68 kD), lamin C (62 kD),  a lamina- 
associated protein of 70 kD (solid triangle), vimentin (56 
kD), and actin (43 kD). We have determined that the 70 kD 
isoprenylated protein is lamina-associated based on (a) its 
biochemical characteristics and (b) immunofluorescence lo- 
calization and immunoblot identification by a chicken lamin 
B2-specific antibody (Beck, L. A., C. H. Campbell, J. Logel, 
and M. Sinensky, submitted for publication).  The fluorogram 
of this 2D-NEPHGE gel is presented in Fig.  1 C. The two 
R-[2-~4C]mevalonate-labeled  polypeptides in the acidic re- 
gion of the 2D-NEPHGE gel are lamin B and the 70-kD 
lamina-associated polypeptide (solid triangle). As we previ- 
ously reported (5),  the R-[2-t4C]mevalonate-labeled poly- 
peptide in Fig. 1 C, with an apparent molecular mass of 74 
kD but no visible silver-staining mass is the lamin A precur- 
sor (designated as lamin Ao [17]). 
The silver-stained 2D-NEPHGE gel of a nuclear lamina 
intermediate filament fraction from similarly treated HeLa 
cells contains a similar complement of proteins (Fig.  1 B). 
The 74 kD prelamin A polypeptide (Ao) and lamin B are la- 
beled by R-[2-14C]mevalonate.  However,  in HeLa cells, in 
contrast to  CHO-K1,  there  are  two  R-[2-~4C]mevalonate- 
labeled lamina-associated polypeptides (D, solid triangles) 
that display lower molecular masses and more basic isoelec- 
The Journal of Cell Biology, Volume II0,  1990  1490 Figure 1. Identification of R-[2-~4C]mevalonate-labeled proteins in CHO-KI and HeLa nuclear lamina-intermediate  filament preparations 
by 2D-NEPHGE and fluorography. CHO-K1 and HeLa cells were labeled with 2/zCi/ml R-(2-~4C) mevalonate for 17 h in medium IV. 
Nuclear lamina intermediate  filament fractions were analyzed by 2D-NEPHGE and fluorography as previously described  (4). Proteins 
were visualized by silver staining. (A) Silver-stained CHO-K1 nuclear lamina intermediate filament preparation.  (B) Silver-stained HeLa 
nuclear lamina intermediate  filament preparation.  (C and D) Fluorograms  of the 2D-NEPHGE gels in A and B, respectively.  Only the 
relevant portion of each fluorogram is shown.  Fluorographic  exposure was for 45 d.  Indicated are lamins A (72 kD), B (68 kD), and 
C (62 kD); the 74-kD isoprenylated prelamin A polypeptide (Ao), the 70-kD lamina-associated isoprenylated polypeptide (solid triangle), 
vimentin (v), and actin (a).  The arrows in A and B (as well as in subsequent figures) indicate the relative position of prelamin  A (Ao) 
and lamin A in C and D as determined  by superimposing  each fluorogram on its silver-stained  gel. 
tric points than does the 70 kD lamina-associated CHO-K1 
homologue (compare the solid triangles in the silver-stained 
gels [,4 and B] with the corresponding fluorograms [C and 
/9]). 
Immunological Identification of Prelamin A 
and Lamin A  in Nuclear Lamina Intermediate 
Filament Preparations 
We have shown (4) that prelamin A migrates on 2D-NEPHGE 
gels with an identical set of pH isovariants and at a slightly 
higher molecular mass than lamin A, is precipitated with an- 
tilamin (A  +  C) antiserum,  and exhibits peptide mapping 
homology with  lamin A.  We now present immunological 
evidence identifying the 74-kD R-[2-~4C]mevalonate-labeled 
polypeptide  as  prelamin  A.  Nuclear  lamina  intermediate 
filament fractions were prepared from HeLa cells labeled 
with  [35S]methionine  for 7  h  and  then  shifted  to  medium 
containing mevinolin and [35S]methionine  for an additional 
10 h. Visible in the autoradiogram, produced by the [35S]me- 
thionine-labeled polypeptides transferred to nitrocellulose, 
(Fig. 2 A) is newly synthesized prelamin A (Ao), which ac- 
cumulates under conditions of mevalonate starvation.  Also 
present in these ceils is mature lamin A that was synthesized 
and processed during the preliminary 7 h growth in the ab- 
sence of mevinolin. In contrast, the autoradiogram from cells 
not treated with mevinolin (Fig.  2  B)  illustrates  that cells 
grown in the absence of mevinolin process prelamin A nor- 
mally. 
Positive identification of these polypeptides as prelamin A 
and lamin A was made by immunoblot analysis using an an- 
tilamin (A+C) serum.  Both prelamin A  and mature lamin 
A, (Fig. 2 C) are present in mevinolin-treated cells. In con- 
trast, only lamin A  is detectable in the immunoblots from 
untreated cells (D). Immunoblot analyses of nuclear lamina 
intermediate filament preparations from a number of simi- 
larly treated cell types yield identical results (Beck, L.  A., 
C. H. Campbell, J.  Logel, and M.  Sinensky, submitted for 
publication).  Both the 74  kD R-[2-~4C]mevalonate-labeled 
polypeptide and the 72 kD nonisoprenylated lamin A are rec- 
ognized by an antilamin (A  +  C) antibody, consistent with 
their identification as lamin A and its precursor polypeptide, 
prelamin A. Only in mevinolin-treated cells, in the absence 
of any exogenously added mevalonate, does prelamin A ac- 
cumulate to a detectable level (Fig. 2 A). Even the addition 
of  trace  amounts  of  mevalonate,  present  only  as  R-[2- 
'4C]mevalonate, results in a  sufficient intracellular concen- 
tration of mevalonate to allow biosynthesis of isoprenoids, 
posttranslational modification, and processing ofprelamin A 
Beck et al. lsoprenylation-dependent Processing of Prelamin A  1491 Figure 2. Immunobiot analysis of the accumulation of prelamin A in mevinolin-treated cells.  HeLa cells were grown for 7 h in medium 
V containing  100 #Ci/ml [35S]methionine. The labeling medium was then changed to either medium V with 100 ~Ci/ml [35S]methionine 
and 5 #g/ml mevinolin (A) or to medium V (no mevinolin) with  100 #Ci/ml [35S]methionine (B). After an additional  10 h of growth, 
nuclear lamina intermediate  filament fractions were prepared,  displayed on 2D-NEPHGE gels,  and transferred  to nitrocellulose mem- 
branes.  [35S]methionine-labeled polypeptides  were visualized autoradiographically  from the nitrocellulose blots with Kodak X-OMAT 
AR film. After autoradiography,  immunoblot analysis was then performed. A  1:1,000 dilution of human autoimmune antilamin  (A + 
C) serum was used as the primary antibody and a  1:2,000 dilution of alkaline phosphatase conjugated goat anti-human IgG was used 
as the second antibody. Indicated are prelamin A (A,,), lamins A, B, and C, vimentin (v), cytokeratin  (ck), and actin (a). (A) Autoradio- 
gram obtained from the nitrocellulose blot of nuclear lamina intermediate  filament preparation  from mevinolin-treated  HeLa cells.  (B) 
Autoradiogram obtained from the nitrocellulose blot of nuclear lamina intermediate filament preparation  from the untreated HeLa cells. 
(C) Immunoblot from A. (D) Immunoblot from B. 
(Fig.  1 A and B).  The R-[2-~4C]mevalonate-labeled 74-kD 
pre-lamin A  fiuorographic signal (Fig.  1,  C and D) is pro- 
duced by those molecules of prelamin A that have been mod- 
ified by the mevalonate-derived product but have not yet been 
processed. 
Verification of the Isoprenoid Nature of the 
Mevalonate-derived Modification 
(3-R,S)-3-Fluoromevalonate is a competitive inhibitor (41) 
of pyrophosphomevalonate  decarboxylase. This enzyme cata- 
lyzes the reaction leading directly to isopentenyl pyrophos- 
phate, the immediate precursor to all isoprenoids. Treatment 
ofCHO met-18b-2 cells with (3-R,S)-3-fluoromevalonate in- 
hibits the  posttranslational  modification of proteins with a 
metabolic product derived  from R-[2-~4C]mevalonate in  a 
dose-dependent manner (Fig.  3 A, solid circles).  Inhibition 
by (3-R,S)-3-fluoromevalonate is specific for the isoprenyl- 
ated proteins, since it produces only a slight effect on the in- 
corporation of [35S]methionine into total cellular protein (Fig. 
3 A, open circles).  Consistent with the postulated isoprenoid 
nature of this type of modification to the lamina proteins, (3- 
R,S)-3-fiuoromevalonate  blocks  the  R-[2-~*C]mevalonate  - 
derived labeling of proteins of nuclear lamina intermediate 
filament preparations (Fig. 3 B, solid circles) with little effect 
on the net synthesis of these proteins as measured by psS]me- 
thionine labeling (Fig. 3 B, open circles).  These results are 
consistent with the premise that the mevalonate-derived mod- 
ification to prelamin A, as well as to other mevalonate-labeled 
proteins,  is  isopentenyl  pyrophosphate,  or  an  isoprenoid 
moiety metabolically distal to isopentenyl pyrophosphate. 
Inhibition of the Processing of Prelamin A  to Lamin A 
Is Not Due to Nonspecific Mevinolin Effects 
It was important to confirm that the block to prelamin A pro- 
cessing  is  a  direct consequence of mevinolin depletion  of 
isoprenoids, and is not due to nonspecific mevinolin effects. 
We compared the processing of prelamin A  in mevinolin- 
treated CHO-K1 and HeLa cells to the processing of prelam- 
in A in a cell line auxotrophic for mevalonate (mev-l), grown 
under  conditions  of mevalonate starvation.  These  studies 
demonstrate (Fig. 4) that only mature lamin A is present in 
control CHO-K1 or HeLa cells grown in the absence of mev- 
inolin (Fig. 4, lanes a and d), or in Mev-1 cells supplemented 
with exogenous mevalonate (Fig. 4,  lane g).  Accumulation 
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Figure 3.  (3-R,S)-3-Fluoromevalonate  inhibition of R-[2J4C]mev - 
alonate incorporation  into isoprenylated proteins.  CHO-KI (met- 
18b-2) cells were preincubated  in the absence of radioisotopes for 
2 h (to deplete endogenous pools of mevalonate) in either medium 
IV (for R-[2-'4C]mevalonate labeling) or medium V (for [35Slme- 
thionine labeling) containing 8/zg/ml mevinolin and 0-500/zg/mi 
(3-R,5)-3-fluoromevalonate.  At 2 h, an equal volume of medium 
IV containing 5 #Ci/ml R-[2-14Clmevalonate  or medium V contain- 
ing 60/zCi/ml  [35S]methionine with the appropriate (3-R,S)-3-fluo- 
romevalonate concentrations was added. Labeling was then allowed 
to proceed for an additional  17 h.  Duplicate aliquots,  containing 
equal numbers of cells,  were analyzed for total [3SS]methionine or 
R-[2-t4C]mevalonate incorporation into protein using the filter bind- 
ing assay described  in Materials and Methods.  (A) Dose-response 
curve for the (3-R,S)-3-fluoromev~onate inhibition of R-[2-'~C]me  - 
valonate  incorporation  into cellular  isoprenylated  proteins  (solid 
circles),  and  [35S]methionine incorporation  into cellular  protein 
(open circles). (B) Dose response curve for the (3-R,S)-3-fluoro- 
mevalonate  inhibition of R-[2J*C]mevalonate  incorporation  into 
protein in nuclear lamina intermediate filament preparations  (solid 
circles) and [35S]methionine incorporation into proteins of nuclear 
lamina intermediate  filament fractions  (open circles). 
of prelamin A  can be manifested either by mevinolin treat- 
ment of CHO-K1 or HeLa cells (Fig. 4, lanes b and e) with 
mevinolin, or by growth of Mev-1  in the absence of exoge- 
nous mevalonate (Fig. 4, lane h). To test further that process- 
ing of prelamin A is mevalonate-dependent, cells were treated 
simultaneously with mevinolin and mevalonate. Under these 
growth conditions, cells contain only mature lamin A  (Fig. 
4, lanes c,f, and i). These results demonstrate that (a) mev- 
alonate  starvation,  whether the consequence  of mevinolin 
treatment or auxotrophy, blocks the processing of prelamin 
A; and (b) the presence of mevalonate, even during mevino- 
lin treatment, restores isoprenoid synthesis and allows pro- 
cessing of prelamin A  to lamin A. 
Kinetics of Prelamin A  Processing: 
lmmunoprecipitation  Analysis 
We next examined the kinetics of the isoprenoid-dependent 
processing  of prelamin A.  Both  HeLa and  CHO-K1  cells 
were labeled for  17 h  with psS]methionine plus mevinolin 
to  accumulate  newly  synthesized  35S-labeled  prelamin  A. 
Processing  was  initiated  by  removing  the  mevinolin  and 
[3~S]methionine  labeling medium and adding fresh medium 
containing  1 mM unlabeled mevalonate. Disappearance of 
the [35S]methionine  labeled 74-kD prelamin A precursor and 
the concomitant appearance of mature 72-kD lamin A  was 
monitored by immunoprecipitation with antilamin (A  +  C) 
antiserum, SDS-PAGE, and fluorography. HeLa cells grown 
in the absence of mevinolin contain only the mature form of 
lamin A (Fig. 5 A, lane a), whereas cells treated with mev- 
inolin accumulate [35S]methionine-labeled prelamin A (Fig. 
5 A, lane b). The mevalonate-induced chase of prelamin A 
Figure 4. Immunoprecipitation analysis of prelamin A in mevino- 
lin-treated cells.  Immunoprecipitation  analysis,  SDS-PAGE,  and 
fluorography ofCHO-KI, HeLa, and mev-1 cells, labeled for 17 h 
with 50/zCi/ml [3~S]methionine were performed as previously de- 
scribed (4). (Lanes a-c) CHO-KI cells grown in normal (medium 
V) medium (lane a), medium V with 5/zg/ml mevinotin (lane b), 
or medium  V  with  5 #g/ml mevinolin  plus  l-mM mevalonate. 
(Lanes d-f) HeLa cells grown in normal (medium V) medium (lane 
d), medium V with 5 ttg/ml mevinolin (lane e), or medium V with 
5 #g/ml mevinolin plus 1 mM mevalonate. (Lanes g-i) Mev-I cells 
grown  in medium V supplemented with  1 mM mevalonate (lane 
g), or medium V only (lane h), or medium V with 5 #g/ml mevino- 
lin plus 1 mM mevalonate (lane i). The presence (+) or absence 
(-) of mevinolin (MVN) or mevalonate (MVL) is indicated in the 
legend at the top of the figure. Arrows identify prelamin  A (A,), 
lamin A, and lamin .C. 
Beck et al. lsoprenylation-dependent  Processing  of Prelamin A  1493 Figure 5. Time course analysis of the isoprenylation-dependent processing of prelamin  A. HeLa cells were grown for 17 h in medium 
V containing  100 #Ci/ml [35S]methionine and 5 #g/ml mevinolin.  Mev-1 cells were grown in the same medium without mevinolin. To 
initiate the isoprenylation-dependent  conversion  of the [35S]methionine-labeled prelamin  A to lamin A, labeling medium was replaced 
with medium I containing  1 mM unlabeled mevalonate.  At appropriate  intervals,  cells were harvested  in situ with solubilization buffer. 
Details of the immunoprecipitation procedure using antilamin A +  C autoimmune serum, as well as SDS-PAGE and fluorography have 
been described (4). (A) SDS-PAGE/fluorographic  analysis of the time course of the isoprenylation-dependent conversion of prelamin A 
to lamin A in HeLa cells.  (Lane a) 17 h, no mevinolin treatment;  (lane b) 17 h with mevinolin treatment;  (lanes c-i) mevalonate chase 
of prelamin A to lamin A at 10 min (lane c); 35 min (lane d); 60 min (lane e); 80 min (lane f);  100 min (lane g);  180 min (lane h); 
and 240 min (lane i) after removal of mevinolin and the shift to mevalonate-containing growth medium. (B) SDS-PAGE/fluorographic 
analysis of the conversion of prelamin A to lamin A in mev-I cells. (Lane a) 17 h growth under mevalonate starvation conditions; (lanes 
b-i) mevalonate induced chase of prelamin  A to lamin A at 20 min (lane b); 35 min (lane c); 45 min (lane d);  105 min (lane e);  120 
min (lane f);  180 min (lane g); 240 min (lane h); and 300 min (lane i) after removal of mevinolin and shift to mevalonate-containing 
growth medium.  Indicated are the 74-kD prelamin  A polypeptide  (A,), the 72-kD mature lamin A form (A), and lamin C (C). 
into lamin A  (Fig.  5 A, lane c-i) reveals a time-dependent 
processing  of [35S]methionine-labeled  prelamin A.  Lamin 
A processing is first detectable 60 min after the addition of 
exogenous mevalonate (Fig. 5 A, lane e). By 100 min (Fig. 
5 A, lane g), approximately half of the prelamin A, that accu- 
mulated during the mevinolin block, has been converted to 
lamin A. By 240 min (lane i), all of the prelamin A has been 
converted to lamin A. Identical results were obtained using 
the mevalonate auxotroph Mev-1 (Fig. 5 B). Only prelamin 
A is present in Mev-1 cells starved for mevalonate (Fig. 5 B, 
lane a). Processing of prelamin A is first detectable ~45 min 
(lane d)  after mevalonate addition.  By  180  min  (lane g), 
all of the [35S]methionine  labeled prelamin A has been pro- 
cessed to lamin A. 
Kinetics of  Prelamin A Processing: 
2D-NEPHGE Analysis 
As an independent method of examining the kinetics of prelam- 
in A processing, we used a 2D-NEPHGE/fluorographic anal- 
ysis  of nuclear  lamina  intermediate  filament preparations 
from HeLa cells labeled with  [35S]methionine  in  the pres- 
ence or absence of mevinolin. Consistent with the data ob- 
tained from the immunoprecipitation analysis of untreated 
HeLa cells  (Fig.  5  A,  lane  a),  we  found  that  all  of the 
[35S]methionine  labeled lamin A in nuclear lamina interme- 
diate filament preparations from untreated cells is present as 
the mature 72-kD form (Fig. 6 A; note the absence of prelam- 
in A). In mevinolin-treated cells, processing is blocked and 
the lamin A precursor polypeptide accumulates (Fig. 6 B). 
The rate of conversion of [35S]methionine-labeled prelamin 
A  to lamin A  from parallel cultures,  that had been trans- 
ferred to unlabeled chase medium containing  1 mM exoge- 
nous mevalonate (Fig. 6 C-F), was identical to the data pre- 
sented in Fig. 5 A. By 120 min (Fig. 6 D), after release from 
the mevinolin block, most of the prelamin A has been con- 
verted to lamin A. From 120 to 250 min after the addition 
of mevalonate (Fig. 6 D, E, and F), there is a steady decrease 
in prelamin A  accompanied by a  concomitant increase in 
lamin A. At 250 min (F), newly synthesized prelamin A  is 
no longer detectable. 
Quantitation of the Precursor Product Relationship 
between Prelarain A  and Lamin A 
Radioactive spots corresponding to prelamin A,  lamin A, 
and 13 other well-separated and clearly distinguishable [35S]- 
methionine-labeled polypeptides were excised from a repre- 
sentative  subset  of 2D-NEPHGE gels  obtained  from this 
analysis and counted.  The fractional change in the amount 
The Journal of Cell Biology, Volume  110, 1990  1494 Figure 6. 2D-NEPHGE analysis of the precursor product relationship between prelamin A and lamin A in HeLa. Experimental conditions 
are given in the legend to Fig. 5. At intervals after the addition of exogenous mevalonate, cells were collected and counted. For subsequent 
2D-NEPHGE analysis, a micropreparation procedure for isolation of the nuclear lamina intermediate filament fraction was used. This 
method paralleled the large scale nuclear lamina intermediate filament isolation procedure previously described (4). The resulting nuclear 
lamina intermediate filament fractions were solubilized in 63 mM Tris-HCl (pH 7.5), 2% SDS, 5%/3-mercaptoethanol, 8 M urea, and 
stored at -80°C.  2D-NEPHGE analysis and fluorography were performed as described (4). Fluorograms from a representative subset 
of these 2D-NEPHGE gels are presented in A-F. (A) Control, 17 h growth in 35S-labeling medium without mevinolin. (B)  17 h growth 
with 5 #g/ml mevinolin. Arrows for prelamin A (A,,) in A and for lamin A (A) in B are for orientation purposes. (C-F) Mevalonate- 
induced chase of prelamin A to lamin A after removal of mevinolin and shift to mevalonate-containing growth medium. (C) 90 min after 
release from mevinolin block. (D) 120 min; (E) 200 min; (F) 250 min. Indicated are lamins A, B, C, the 74-kD prelamin A polypeptide 
(A,), vimentin (v), cytokeratin (ck), and actin (a). Electrophoresis in the NEPHGE dimension was for 3,000 V h. 
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Figure 7.  Quantitation of the precursor product relationship be- 
tween prelamin A and lamin A. A subset of the fluorograms ob- 
tained from the 2D-NEPHGE/fluorographic analysis of  the prelam- 
in A to lamin A processing (see Fig. 6) were used as templates 
to carefully excise the [3SS]methionine-labeled  prelamin A, lamin 
A, and  13 other well-separated and clearly identifiable polypep- 
tides. The gel slices were dissolved in 30% hydrogen peroxide at 
65°C, and the radioactivity was contained in each polypeptide de- 
termined by liquid scintillation counting. The fractional ratio of  the 
radioactivity contained in each polypeptide spot, relative to the to- 
hal radioactivity contained in all 15 spots, was then determined. 
The fractional change in prelamin A (Ao, open circle) and lamin 
A (A, solid circle) as a function of time after release from the 
mevinolin treatment is presented. 
tent with the premise that the loss of the isoprenoid substi- 
tuent is associated with the proteolytic processing mechanism 
during the conversion of prelamin A to lamin A. 
Discussion 
In earlier reports we have shown that prelamin A, lamin B, 
and a 70 kD lamina-associated polypeptide are posttransla- 
tionally modified with a metabolite derived from R-[2J4C] - 
mevalonate (4).  In this  report we confirm the  isoprenoid 
nature of this modification by demonstrating that (3-R,S)-3- 
fluoromevalonate inhibits  the  incorporation  of  R-[2-14C] - 
mevalonate into these proteins (Fig. 3). We have identified 
the 74 kD isoprenylated protein as prelamin A on the basis 
of its subcellular distribution,  migration on 2D-NEPHGE 
gels, and peptide maps (4). Furthermore, it is recognized on 
2D-NEPHGE/immunoblots with antilamin  (A  +  C)  anti- 
bodies (Fig. 2).  Mevalonate starvation and subsequent de- 
pletion of isoprenoid pools can be  effected by  mevinolin 
treatment or through auxotrophy (Fig.  4).  The metabolic 
consequence of either treatment is inhibition of isoprenoid- 
dependent proteolytic processing, rapidly followed by an ac- 
cumulation of  prelamin A. Subsequent addition of mevalonate 
abolishes isoprenoid starvation and allows in vivo conver- 
sion of prelamin A to lamin A (Figs. 5 and 6). The rate of 
this conversion (Fig. 7) is similar to the loss of  the isoprenoid 
moiety from prelamin A (Fig. 8 B). 
of radioactivity contained in the prelamin A  and lamin A 
polypeptide spots, relative to the totalradioactivity contained 
in all 15 spots, was then determined. The result of  this exami- 
nation (Fig. 7) demonstrates that (a) prelamin A accumulates 
as a consequence of a mevinolin-induced isoprenoid starva- 
tion; (b) prelamin A is converted to lamin A with a half-life 
of ~90-120 min after the removal of the mevinolin block; 
and (c) prelamin A and lamin A exhibit a precursor product 
relationship. 
Kinetics of the Loss of the lsoprenoid Substituent from 
Prelamin A 
We next compared the rate of loss of the isoprenoid moiety 
from prelamin A with the rate of conversion of prelamin A 
to lamin A.  [SH]isoprenylated lamins in Mev-1 cells were 
obtained  by  growth  in  medium  IV  with  R,S-[5-SH(N)]  - 
mevalonate for 17 h. The labeling medium was removed and 
replaced with  fresh medium containing  1 mM  unlabeled 
mevalonate. At various times from 0 to 30 h, cells were har- 
vested and nuclei prepared. The rate of loss of the tritium 
label  ([3H]isoprenylation)  from  the  isoprenylated  lamina 
proteins was analyzed by SDS-PAGE and fluorography. The 
resultant fluorogram (Fig. 8 A) was then analyzed by den- 
sitometry. The results of this analysis are presented in Fig. 
8 B. The loss of the isoprenoid substituent from prelamin A 
is relatively rapid, displaying a half-life, determined graphi- 
cally, of '~100-120 min. In contrast, lamin B and the 70-kD 
lamina-associated protein are characterized by a very stable 
form of isoprenylation. This rate of loss of the isoprenylated 
substituent from prelamin A is comparable to the rate of con- 
version of prelamin A to lamin A, as determined from the 
immunoprecipitation and 2D-NEPHGE/fluorographic anal- 
yses presented in Figs. 5, 6, and 7. These results are consis- 
The -C-A-A-X Carboxy Terminal Motif of  Prelamin A 
Is Required for Its Maturation to Lamin A 
Clarke et al. have catalogued a number of proteins that con- 
tain a -C-A-A-X carboxy terminal amino acid sequence (10). 
They have suggested that this consensus amino acid sequence 
may provide a general recognition site for posttranslational 
modifications  that  include  lipidation  and  carboxymethyl- 
ation. This sequence is present in yeast peptidyl pheromones 
(3, 5, 38, 46), yeast rasl and ras2 (43, 46), and mammalian 
p21 r~ (8,  10,  19, 21, 46, 57). Mammalian and avian lamins, 
characterized by a -C-A-A-M  carboxy terminal motif (55), 
can be considered a subfamily of this class of proteins. The 
similarity between the -C-A-A-X motif of ras proteins, yeast 
peptidyl pheromones, and the -C-A-A-M motif of lamins, in 
addition to their posttranslational isoprenylation, suggests 
that the functional role of this carboxy terminal sequence 
may be similar. Moreover, ms proteins, yeast peptidyl pher- 
omones, and B-type lamins undergo proteolytic processing 
and membrane localization subsequent to isoprenylation. We 
propose, as has Holtz et al. (22), that prelamin A is also a 
nuclear membrane protein and that nuclear membrane local- 
ization is required for its processing and assembly into the 
lamina. The isoprenylated form of prelamin A  is hypothe- 
sized to be required for this membrane localization. 
lsoprenylation Is Required for the Processing of 
Prelamin A  to Lamin A 
We have demonstrated that depletion of endogenous isopre- 
noid pools through mcvinolin treatment can block the pro- 
cessing of prelamin A.  This occurs in HeLa and CHO-K1 
cells (Figs.  1, 2, and 4), as well as in a number of other hu- 
man, hamster, and chicken cell lines (our unpublished data). 
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[3H]isoprenylated  prelamin A by SDS-PAGE and 
fluorography. Mev-1 cells were labeled in medium 
IV for 17 h with 10 t~Ci/ml of R,S-[5-3H(N)]mev  - 
aionate. To initiate the mevalonate-induced turn- 
over of the [3H]mevalonate-labeled prelamin A, 
cells (in duplicate) were incubated with medium I 
containing 1 mM cold mevalonate. At the times 
indicated, nuclei were prepared (4) and examined 
by SDS-PAGE and fluorography.  Densitometry 
of the fluorogram in ,4 was used to quantitate the 
rate of loss of the [3H]isoprenylated moiety from 
the  isoprenylated  nuclear  lamina  proteins.  (A) 
Fluorogram of  the SDS-PAGE analysis of  the loss 
of tritium  label from the  [3H]isoprenylated nu- 
clear lamina intermediate filament proteins as a 
function of time of mevalonate chase.  (Lane a) 
Control;  (lanes b-g)  time  after  initiation  of 
mevalonate  chase: 1.5 h (lane b); 2.5 h (lane c); 6.1 
h (lane d); 9.6 h (lane e); 18.4 h (lane f); 25.1 h 
(lane g). Molecular mass standards (in kilodaltons) 
are  presented  at  the  right  of  the  fluorogram. 
Fluorographic exposure was for 90 d. (B) Results 
of densitometric analysis of the fluorogram in A. 
Indicated are the 74-kD isoprenylated prelamin A 
polypeptide  (solid triangle), the  70-kD lanfina- 
associated polypeptide (p70, solid  circle),  and 
lamin B (open triangle). 
Starvation of  the mevalonate auxotroph Mev-1 (Fig. 4) verifies 
that the inhibition of prelamin A processing is a specific con- 
sequence of isoprenoid starvation and  is  not due  to  non- 
specific mevinolin effects.  Furthermore,  the  inhibition of 
processing is readily reversible. In mevinolin-treated cells, 
addition of  exogenous mevalonate initiates protein isoprenyl- 
ation, followed rapidly (Fig. 4) by the in vivo conversion of 
prelamin A  (74 kD)  to mature lamin A  (72 kD).  In vivo 
studies  on  the  fate  of recombinant prelamin  A  (22,  55), 
Xenopus lamins Lt and A (29), and chicken lamin B2 (55), 
modified by site-directed mutagenesis,  have demonstrated 
the importance of the -C-A-A-M cysteine residue for proper 
nuclear envelope assembly and proteolytic maturation. Vor- 
burger et al. have demonstrated that the in vitro isoprenyla- 
tion  and  proteolytic processing  of chicken  lamin  B2  are 
blocked by a cysteine to alanine mutation in the -C-A-A-M 
motif  (55). In addition, they have demonstrated that this pro- 
cessing pathway is mevalonate dependent. Similarly, a cys- 
teine to methionine mutation in the -C-A-A-M  motif of hu- 
man prelamin  A  blocks nuclear envelope association and 
proteolytic processing (22). These mutational studies on the 
presumed isoprenylation site of these proteins are also con- 
sistent with our proposal that isoprenylation is required for 
the processing of prelamin A. 
Processing of Prelamin A  Involves the Loss of the 
lsoprenylated Moiety 
Analysis of mature lamin A by peptide mapping revealed that 
the entire carboxy terminal -C-A-A-M  motif of prelamin A 
is cleaved during maturation, whereas in lamin B2 at most 
three amino acids are lost (55, 56). We have clearly demon- 
strated (Figs.  1 and 8, and reference 4) that, lamin B retains 
its isoprenylation, whereas mature lamin A does not. Lamin 
C, which is missing the carboxy terminal 93 amino acids that 
are present in lamin A (13, 36), is not isoprenylated (Fig.  1; 
reference 4), further supporting the premise that the -C-A-A-M 
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the carboxy-terminal 14-kD fragment of mature murine lamin 
A has revealed that mature lamin A lacks the carboxy termi- 
nal 18 amino acids predicted from the prelamin A cDNA se- 
quence (13, 36),  thus providing direct evidence that mam- 
malian prelamin A maturation occurs by carboxy terminal 
proteolysis. It is reasonable, therefore, to presume that the 
polypeptide removed from prelamin A during the endopro- 
teolytic processing event contains the isoprenylated moiety. 
In agreement with this assumption, is our demonstration that 
the rate of loss of isoprenylation from prelamin A (Fig. 8) 
is similar to the rate of conversion of prelamin A to lamin 
A (Figs. 5-7).  These lines of evidence, combined with our 
in vivo demonstration of mevalonate dependency for the con- 
version of prelamin A to lamin A, are not consistent with the 
earlier suggestion (32) that the 72-kD lamin A polypeptide 
arises artifactually. 
The data presented here support the hypothesis that the 
loss of isoprenylation from prelamin A during maturation is 
due to its localization (presumably the cysteine residue of the 
-C-A-A-M motif) at the carboxy terminus. Confirmation of 
this premise must await chemical identification of the deriva- 
tized amino acids and direct sequencing of the carboxy ter- 
minus of prelamin A. 
Prelamin A Maturation: Similarity to Other Systems 
The sequence of metabolic events implicated in the matura- 
tion of prelamin A is analogous to that described for yeast 
peptidyl pheromones and ras proteins. In Tremella mesen- 
terica, the mating pheromone tremerogen A-10, is isopren- 
ylated with a farnesyl substituent in a thioether linkage to the 
carboxy terminal cysteine residue of the -C-A-A-X motif (39, 
40). After isoprenylation, the 26-kD precursor polypeptide 
becomes membrane bound where it is processed to a 24-kD 
polypeptide and the 2-kD mature pheromone (39, 40). In like 
manner, Saccharomyces cerevisiae a-mating factor is syn- 
thesized as a  higher molecular mass precursor and, after 
isoprenylation of the -C-A-A-X cysteine residue with a far- 
nesyl moiety, undergoes endoproteolytic as well as carboxy 
terminal processing (3, 46).  Other studies have shown that 
both carboxy terminal processing and membrane localiza- 
tion of p21 r'~ are dependent on isoprenylation (3,  10, 19, 21, 
46, 57). 
Processing of  Prelamin A: A Proposed Model 
Our results, together with those presented by a number of 
other laboratories, enable us to propose the following model 
for the isoprenylation-dependent maturation of prelamin A. 
Prelamin  A  is  transported  rapidly  into the  nucleus after 
translation.  We hypothesize that,  in analogy to steps  de- 
scribed above for the maturation of p21 r~s, yeast peptidyl 
pheromones,  and  chicken  lamin B2,  prelamin  A  is  then 
isoprenylated, presumably at the cysteine of the carboxy ter- 
minal -C-A-A-M motif. This facilitates its association with 
the nuclear membrane, the site of the subsequent proteolytic 
removal of three C-terminal amino acid residues. This car- 
boxypeptidase-type processing of prelamin A yields a pre- 
lamin A  intermediate containing an isoprenylated carboxy 
terminal cysteine. The nature of the isoprenylation reaction 
is not yet understood, however,  in preliminary studies we 
have found that nonisoprenylated prelamin A is transported 
into the nucleus. In the final stage of the maturation pathway, 
a membrane-bound endopeptidase cleaves an additional poly- 
peptide from the carboxy terminus of prelamin A. The loss 
of this polypeptide, which presumably contains the isopre- 
noid substituent, accounts for the 2-kD molecular mass shift 
observed during maturation of prelamin A. Whether other 
posttranslational modifications are also involved in the altered 
mobility observed during processing of prelamin A is still 
not known. 
Additional mammalian proteins that undergo an isopren- 
ylation-dependent proteolytic maturation most likely exist 
since mevinolin treatment has been shown to alter the elec- 
trophoretic mobility of a number of cytosolic, isoprenylated 
proteins in murine erythroleukemic cells (44). The variabil- 
ity in the fate of the isoprenylated moiety, and the proteins 
so modified, advances the possibility of different isoprenoid 
substituents,  multiple prenyl-transferases, endopeptidases, 
and/or carboxy peptidases involved in this pathway for pro- 
teolytic maturation. 
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